TY - JOUR
T1 - Association of a Remote Patient Monitoring (RPM) Program with Reduced Hospitalizations in Cancer Patients with COVID-19
AU - Pritchett, Joshua C.
AU - Borah, Bijan J.
AU - Desai, Aakash P.
AU - Xie, Zhuoer
AU - Saliba, Antoine N.
AU - Leventakos, Konstantinos
AU - Coffey, Jordan D.
AU - Pearson, Kristina K.
AU - Speicher, Leigh L.
AU - Orenstein, Robert
AU - Virk, Abinash
AU - Ganesh, Ravindra
AU - Paludo, Jonas
AU - Halfdanarson, Thorvardur R.
AU - Haddad, Tufia C.
N1 - Publisher Copyright:
© American Society of Clinical Oncology.
PY - 2021/9/1
Y1 - 2021/9/1
N2 - PURPOSE:The goal of this study was to assess the impact of an interdisciplinary remote patient monitoring (RPM) program on clinical outcomes and acute care utilization in cancer patients with COVID-19.METHODS:This is a cross-sectional analysis following a prospective observational study performed at Mayo Clinic Cancer Center. Adult patients receiving cancer-directed therapy or in recent remission on active surveillance with polymerase chain reaction-confirmed SARS-CoV-2 infection between March 18 and July 31, 2020, were included. RPM was composed of in-home technology to assess symptoms and physiologic data with centralized nursing and physician oversight.RESULTS:During the study timeframe, 224 patients with cancer were diagnosed with COVID-19. Of the 187 patients (83%) initially managed in the outpatient setting, those who did not receive RPM were significantly more likely to experience hospitalization than those receiving RPM. Following balancing of patient characteristics by inverse propensity score weighting, rates of hospitalization for RPM and non-RPM patients were 2.8% and 13%, respectively, implying that the use of RPM was associated with a 78% relative risk reduction in hospital admission rate (95% CI, 54 to 102; P =.002). Furthermore, when hospitalized, these patients experienced a shorter length of stay and fewer prolonged hospitalizations, intensive care unit admissions, and deaths, although these trends did not reach statistical significance.CONCLUSION:The use of RPM and a centralized virtual care team was associated with a reduction in hospital admission rate and lower overall acute care resource utilization among cancer patients with COVID-19.
AB - PURPOSE:The goal of this study was to assess the impact of an interdisciplinary remote patient monitoring (RPM) program on clinical outcomes and acute care utilization in cancer patients with COVID-19.METHODS:This is a cross-sectional analysis following a prospective observational study performed at Mayo Clinic Cancer Center. Adult patients receiving cancer-directed therapy or in recent remission on active surveillance with polymerase chain reaction-confirmed SARS-CoV-2 infection between March 18 and July 31, 2020, were included. RPM was composed of in-home technology to assess symptoms and physiologic data with centralized nursing and physician oversight.RESULTS:During the study timeframe, 224 patients with cancer were diagnosed with COVID-19. Of the 187 patients (83%) initially managed in the outpatient setting, those who did not receive RPM were significantly more likely to experience hospitalization than those receiving RPM. Following balancing of patient characteristics by inverse propensity score weighting, rates of hospitalization for RPM and non-RPM patients were 2.8% and 13%, respectively, implying that the use of RPM was associated with a 78% relative risk reduction in hospital admission rate (95% CI, 54 to 102; P =.002). Furthermore, when hospitalized, these patients experienced a shorter length of stay and fewer prolonged hospitalizations, intensive care unit admissions, and deaths, although these trends did not reach statistical significance.CONCLUSION:The use of RPM and a centralized virtual care team was associated with a reduction in hospital admission rate and lower overall acute care resource utilization among cancer patients with COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85116958773&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116958773&partnerID=8YFLogxK
U2 - 10.1200/OP.21.00307
DO - 10.1200/OP.21.00307
M3 - Article
C2 - 34085535
AN - SCOPUS:85116958773
SN - 2688-1527
VL - 17
SP - E1293-E1302
JO - JCO Oncology Practice
JF - JCO Oncology Practice
IS - 9
ER -